Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

Jessica N. Hartnett, Matthew L. Boisen, Darin Oottamasathien, Abigail B. Jones, Molly M. Millett, Diana S. Nelson, Ivana J. Muncy, Augustine Goba, Mambu Momoh, Mohammed Fullah, Chad Mire, Joan B. Geisbert, Thomas Geisbert, Debra L. Holton, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Reyna, Lina M. Moses, Sheik Humarr Khan, Sahr M. Gevao & 6 others Donald S. Grant, James E. Robinson, Christian Happi, Kelly R. Pitts, Robert F. Garry, Luis M. Branco

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.

Original languageEnglish (US)
Pages (from-to)559-584
Number of pages26
JournalFuture Virology
Volume10
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Lassa Fever
Lassa virus
Western Africa
Bioterrorism
Virus Diseases
Therapeutics
Vaccines
Research

Keywords

  • arenaviruses
  • bioterrorism
  • diagnostics
  • epidemiology
  • hemorrhagic fever
  • Lassa fever
  • Lassa virus
  • public health
  • therapeutics
  • vaccines

ASJC Scopus subject areas

  • Virology

Cite this

Hartnett, J. N., Boisen, M. L., Oottamasathien, D., Jones, A. B., Millett, M. M., Nelson, D. S., ... Branco, L. M. (2015). Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virology, 10(5), 559-584. https://doi.org/10.2217/fvl.15.41

Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. / Hartnett, Jessica N.; Boisen, Matthew L.; Oottamasathien, Darin; Jones, Abigail B.; Millett, Molly M.; Nelson, Diana S.; Muncy, Ivana J.; Goba, Augustine; Momoh, Mambu; Fullah, Mohammed; Mire, Chad; Geisbert, Joan B.; Geisbert, Thomas; Holton, Debra L.; Rouelle, Julie A.; Kannadka, Chandrika B.; Reyna, Ashley A.; Moses, Lina M.; Khan, Sheik Humarr; Gevao, Sahr M.; Grant, Donald S.; Robinson, James E.; Happi, Christian; Pitts, Kelly R.; Garry, Robert F.; Branco, Luis M.

In: Future Virology, Vol. 10, No. 5, 01.05.2015, p. 559-584.

Research output: Contribution to journalArticle

Hartnett, JN, Boisen, ML, Oottamasathien, D, Jones, AB, Millett, MM, Nelson, DS, Muncy, IJ, Goba, A, Momoh, M, Fullah, M, Mire, C, Geisbert, JB, Geisbert, T, Holton, DL, Rouelle, JA, Kannadka, CB, Reyna, AA, Moses, LM, Khan, SH, Gevao, SM, Grant, DS, Robinson, JE, Happi, C, Pitts, KR, Garry, RF & Branco, LM 2015, 'Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever', Future Virology, vol. 10, no. 5, pp. 559-584. https://doi.org/10.2217/fvl.15.41
Hartnett JN, Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS et al. Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virology. 2015 May 1;10(5):559-584. https://doi.org/10.2217/fvl.15.41
Hartnett, Jessica N. ; Boisen, Matthew L. ; Oottamasathien, Darin ; Jones, Abigail B. ; Millett, Molly M. ; Nelson, Diana S. ; Muncy, Ivana J. ; Goba, Augustine ; Momoh, Mambu ; Fullah, Mohammed ; Mire, Chad ; Geisbert, Joan B. ; Geisbert, Thomas ; Holton, Debra L. ; Rouelle, Julie A. ; Kannadka, Chandrika B. ; Reyna, Ashley A. ; Moses, Lina M. ; Khan, Sheik Humarr ; Gevao, Sahr M. ; Grant, Donald S. ; Robinson, James E. ; Happi, Christian ; Pitts, Kelly R. ; Garry, Robert F. ; Branco, Luis M. / Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. In: Future Virology. 2015 ; Vol. 10, No. 5. pp. 559-584.
@article{349d7dc1532b4e08b3fbaa5c65cbfd2b,
title = "Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever",
abstract = "Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20{\%} in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60{\%} in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformit{\'e} Europ{\'e}enne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.",
keywords = "arenaviruses, bioterrorism, diagnostics, epidemiology, hemorrhagic fever, Lassa fever, Lassa virus, public health, therapeutics, vaccines",
author = "Hartnett, {Jessica N.} and Boisen, {Matthew L.} and Darin Oottamasathien and Jones, {Abigail B.} and Millett, {Molly M.} and Nelson, {Diana S.} and Muncy, {Ivana J.} and Augustine Goba and Mambu Momoh and Mohammed Fullah and Chad Mire and Geisbert, {Joan B.} and Thomas Geisbert and Holton, {Debra L.} and Rouelle, {Julie A.} and Kannadka, {Chandrika B.} and Reyna, {Ashley A.} and Moses, {Lina M.} and Khan, {Sheik Humarr} and Gevao, {Sahr M.} and Grant, {Donald S.} and Robinson, {James E.} and Christian Happi and Pitts, {Kelly R.} and Garry, {Robert F.} and Branco, {Luis M.}",
year = "2015",
month = "5",
day = "1",
doi = "10.2217/fvl.15.41",
language = "English (US)",
volume = "10",
pages = "559--584",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever

AU - Hartnett, Jessica N.

AU - Boisen, Matthew L.

AU - Oottamasathien, Darin

AU - Jones, Abigail B.

AU - Millett, Molly M.

AU - Nelson, Diana S.

AU - Muncy, Ivana J.

AU - Goba, Augustine

AU - Momoh, Mambu

AU - Fullah, Mohammed

AU - Mire, Chad

AU - Geisbert, Joan B.

AU - Geisbert, Thomas

AU - Holton, Debra L.

AU - Rouelle, Julie A.

AU - Kannadka, Chandrika B.

AU - Reyna, Ashley A.

AU - Moses, Lina M.

AU - Khan, Sheik Humarr

AU - Gevao, Sahr M.

AU - Grant, Donald S.

AU - Robinson, James E.

AU - Happi, Christian

AU - Pitts, Kelly R.

AU - Garry, Robert F.

AU - Branco, Luis M.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.

AB - Lassa fever (LF) is a potentially fatal disease that affects an estimated 300,000-500,000 people in endemic areas of west Africa each year. Though past studies have identified fatality rates of 5-20% in patients suspected to have contracted Lassa virus (LASV), new studies using more precise clinical diagnoses and modern diagnostic assays show fatalities rates above 60% in acutely ill patients from endemic regions. Currently, there are no approved vaccines or therapeutics, and only one Comformité Européenne (CE) marked rapid immunodiagnostic for acute LASV infection. Therefore, preventing LASV transmission is the primary goal in endemic regions. Development of rapid immunodiagnostics and research into the efficacy of current treatment options continues toward saving lives in west Africa as well as creating a line of defense against the nefarious use of LASV in bioterrorism settings.

KW - arenaviruses

KW - bioterrorism

KW - diagnostics

KW - epidemiology

KW - hemorrhagic fever

KW - Lassa fever

KW - Lassa virus

KW - public health

KW - therapeutics

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84930323632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930323632&partnerID=8YFLogxK

U2 - 10.2217/fvl.15.41

DO - 10.2217/fvl.15.41

M3 - Article

VL - 10

SP - 559

EP - 584

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 5

ER -